Healthcare
Large-cap - With a market cap of ₹1201.33 Cr.
EX-Date | Purpose |
---|---|
14 05 2021 | Dividend & Audited Results |
05 08 2021 | Quarterly Results |
26 10 2021 | Quarterly Results |
25 01 2022 | Quarterly Results |
10 05 2022 | Dividend & Audited Results |
29 07 2022 | Quarterly Results |
04 11 2022 | Quarterly Results |
25 01 2023 | Quarterly Results |
12 05 2023 | Audited Results & Quarterly Results & Final Dividend |
26 07 2023 | Quarterly Results |
27 10 2023 | Quarterly Results |
22 01 2024 | Quarterly Results (Revised) |
25 01 2024 | Quarterly Results |
10 05 2024 | Audited Results & Final Dividend |
29 10 2024 | Quarterly Results |
13 05 2025 | Audited Results & Final Dividend |
25 07 2025 | Quarterly Results |
Post-acquisition, Cipla EU’s stake in the subsidiary, will increase to 93.10%
The company had received approval from board of directors to transfer Generics Business Undertaking
Accordingly, Cipla will now hold 22.99% stake on a fully diluted basis in GoApptiv
The investment is expected to be completed on or before February 28, 2025
The inspection concluded with zero Form 483 observations
On conclusion of the inspection, the company has received 6 inspectional observations in Form 483
Upon completion of acquisition, Cipla EU will hold 79.16% stake in the JV Co and balance 20.84% stake will be held by Cooper Pharma
The company has received 2 observations on FDA Form 483 with respect to ANDA filed for the product to be manufactured at the said plant
Total consolidated income of the company increased by 6.65% at Rs 5951.49 crore for Q2FY23
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities and leverage cost synergies in the South African market
The JV entity is being incorporated with an objective of commercialising novel cell therapy products in USA, Japan and EU region
The Board of Directors of the company at its meeting held on November 06, 2023 have inter alia, approved the same
The mobile application is designed to enable the first line of screening for asthma in India
The consideration received from such sale is Rs 59.71 lakh
The product will be available for shipping soon
Besides, the company is betting big on digitisation
Accordingly, Actor will now be a wholly owned step-down subsidiary of the Company
USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024
These six batches were distributed nationwide to wholesalers and retailers
The product is expected to be launched in H1 FY 2025-26 in the United States of America
The affected lot is NB301030, with an expiration date of March 2025
The organization is amongst the first pharmaceutical companies in India & Asia to be part of the Global Lighthouse Network.
Total consolidated income of the company increased by 10.32% at Rs 5873.93 crore for Q4FY23
This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus
The total consolidated income of the company increased by 9.46% at Rs 7019.15 crore for Q4FY25
On conclusion of the inspection, the Company received 8 observations in Form 483
With the completion of this deal, Cipla’s total stake in GoApptiv will increase to 22.99% on a fully diluted basis
CHL shall immediately initiate the distribution and marketing of the said products pending the closure of the proposed acquisition
The proposed sale is expected to be completed by May 31, 2023
Accordingly, CQCIL has now ceased to be a subsidiary of the company with effect from November 14, 2023
This strategic move is aligned with Cipla’s focus on enhancing its consumer healthcare and wellness portfolio
The collaboration aims to leverage the combined expertise and resources of both organisations to develop a safe and efficacious drug for fungal keratitis
Consideration to be received from such sale/disposal is $6.50 million
Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience
This investment will facilitate a Cipla entity’s strategic participation in the Poe diagnostics and AMR space
The company has executed a Facility Demand Guarantee of South African Rand 945 million
USFDA had conducted the inspection at said facility from February 18 to February 20, 2025
USFDA has conducted a cGMP inspection at Cipla’s Pithampur manufacturing facility
The total consideration to be paid for the said acquisition is up to Rs 1.46 crore
The Company will respond to the Warning Letter within the stipulated timelines and work closely with the USFDA
USFDA had conducted the inspection at said facility from January 14 to January 20, 2025
On conclusion of the inspection, Sitec received two observations in Form 483
Nilotinib is an oncology category product in capsule form for oral consumption
USFDA has conducted an inspection at the manufacturing facility of Medispray Laboratories
The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
The recalling of the lot is due to ‘lack of assurance of sterility’
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care
Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico
Total consolidated income of the company increased by 14.58% at Rs 6788.44 crore for Q3FY24
The USFDA had conducted product-specific pre-approval inspection at the Indore plant on June 27 and July 1
The USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved
Total consolidated income of the company increased 6.36% at Rs 5,924.53 crore for Q3FY23
The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’
Total consolidated income of the company increased by 18.01% at Rs 6,465.18 crore for Q1FY24
Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the Company
Plazomicin’s introduction in India underscores Cipla’s proactive response to the urgent global challenge of antimicrobial resistance
The creation of Pactiv as a separate entity allows GoApptiv to segregate its business into distinct sectors i.e., technology and pharmaceuticals
Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium
Total consolidated income of the company increased by 15.17% at Rs 6854.47 crore for Q2FY24
The firm aims to deliver medicines for cardiac, respiratory and other essential chronic therapies as part of the initiative
The company has started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies
Total consolidated income of the company increased by 7.46% at Rs 7294.58 crore for Q3FY25
Accordingly, Cipla EU will now hold 75.10% stake in the JV Co.
There are no data integrity observations
Cipla Med pro Holdings was a dormant entity and this dissolution will not affect performance or revenue of the company
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection
Consolidated total income of the company increased by 5.65% at Rs 7,241.63 crore for Q2FY25
A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets
Earlier, Jay Precision Pharmaceuticals had entered into Share Purchase, Subscription and Shareholder’s Agreement
CiplaRna has been incorporated with the objective of establishing a laboratory for mRNA-based formulation and drug development support
Cipla, Saba Investment, UAE and Shibham Group Holding, UAE have executed Share Purchase agreement on September 28, 2023
On conclusion of the inspection, the company received one observation in Form 483